Arca
Skip to content
Tools
Tools

Lymphoma

Drug research and approvals for lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 1,700 studies of lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 238 drug trials for it since 2013, FDA has 125 approved and 174 open orphan designations naming it, and the EU has 43 authorised medicines for it.

  • Recruiting worldwide: 1,700
  • Trials authorized in Canada: 238
  • FDA orphan approvals: 125
  • EU medicines: 43

Recruiting now

Newest posted first, of 1,700 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 24 of 60

  • CyclophosphamideDNA inhibitor
  • PrednisoneGlucocorticoid receptor agonist
  • RituximabNon-Hodgkin lymphoma · B-lymphocyte antigen CD20 binding agent
  • DexamethasoneGlucocorticoid receptor agonist
  • Brentuximab vedotinHodgkin disease · Tubulin inhibitor
  • IbrutinibMantle-cell lymphoma · Tyrosine-protein kinase BTK inhibitor
  • DacarbazineHodgkin disease · DNA inhibitor
  • LenalidomideFollicular lymphoma · CRL4(CRBN) E3 ubiquitin ligase inhibitor
  • DoxorubicinHodgkin disease · DNA topoisomerase II alpha inhibitor
  • VinblastineHodgkin disease · Tubulin inhibitor
  • BortezomibMantle-cell lymphoma · 26S proteasome inhibitor
  • BleomycinDNA inhibitor
  • ObinutuzumabFollicular lymphoma · B-lymphocyte antigen CD20 binding agent
  • BendamustineNon-Hodgkin lymphoma · DNA inhibitor
  • NivolumabHodgkin disease · Programmed cell death protein 1 inhibitor
  • AcalabrutinibMantle-cell lymphoma · Tyrosine-protein kinase BTK inhibitor
  • PembrolizumabHodgkin disease · Programmed cell death protein 1 inhibitor
  • Polatuzumab vedotinDiffuse large B-cell lymphoma · B-cell antigen receptor complex-associated protein beta chain binding agent
  • ZanubrutinibMantle-cell lymphoma · Tyrosine-protein kinase BTK inhibitor
  • Yttrium y 90 ibritumomab tiuxetanFollicular lymphoma · B-lymphocyte antigen CD20 binding agent
  • MosunetuzumabFollicular lymphoma · T cell surface glycoprotein CD3 binding agent
  • TafasitamabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD19 binding agent
  • GlofitamabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD20 binding agent
  • MethotrexateNon-Hodgkin lymphoma · Dihydrofolate reductase inhibitor

Phase 3 12 of 109

Phase 2 12 of 215

  • PentostatinAdenosine deaminase inhibitor
  • Bryostatin 1
  • TemozolomideDNA inhibitor
  • Carfilzomib26S proteasome inhibitor
  • BlinatumomabNon-Hodgkin lymphoma · T cell surface glycoprotein CD3 cross-linking agent
  • TopotecanDNA topoisomerase I inhibitor
  • UCN-01Cyclin-dependent kinase 2 inhibitor
  • AtezolizumabDiffuse large B-cell lymphoma · Programmed cell death 1 ligand 1 inhibitor
  • DurvalumabDiffuse large B-cell lymphoma · Programmed cell death 1 ligand 1 inhibitor
  • ZidovudineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
  • ClofarabineRibonucleoside-diphosphate reductase RR1 inhibitor
  • DacetuzumabNon-Hodgkin lymphoma · Tumor necrosis factor receptor superfamily member 5 inhibitor

Phase 1 or earlier 12 of 291

How its trials ended

6,428 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 1,774 whose ending is known, 37% met their primary endpoint, 5% missed it and 58% stopped early.

  • Completed, result not reported2,03232%
  • Ongoing1,83128%
  • Status unknown79112%
  • Met its primary endpoint66110%
  • Stopped: other or unclear4637%
  • Stopped: enrollment or feasibility2534%
  • Stopped: sponsor or business decision1893%
  • Missed its primary endpoint821%
  • Stopped: lack of efficacy701%
  • Stopped: funding391%
  • Stopped: safety17<1%

Trials authorized in Canada

The 10 newest of 238; search them all in Canada trials
Oct 30, 2026A phase 2/3 multi-arm, open-label study of MK-1045 in combination with zilovertamab vedotin in participants with relapsed/refractory diffuse large B-cell…MK-1045 / Zilovertamab vedotin (MK-2140)Merck & Co. (MSD)Pending
Oct 16, 2026A phase 3, open label, randomized study comparing the efficacy and safety of odronextamab (REGN1979), an ANTI-CD20 × ANTI-CD3 bispecific antibody, in…Odronextamab (REGN1979)RegeneronPending
Aug 11, 2026A single-arm, phase 2, open-label, multicenter study to evaluate NX-5948 in adults with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) or small…NX-5948Nurix TherapeuticsPending
Jul 23, 2026A phase III study to evaluate the efficacy of surovatamig combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (r-chop) in…SurovatamigAstraZeneca PharmaceuticalsPending
May 6, 2026A phase 3, multiregional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide in participants with relapsed/refractory primary central…Tirabrutinib (ONO-4059) / Rituximab (TRUXIMA) / TemozolomideOno PharmaceuticalPending
Apr 29, 2026A phase 1/2 open-label, multi-center study to evaluate the safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-cell…GSK5926371GSKOngoing
Apr 16, 2026A phase 2/3 randomized, open-label study for MK-1045 in combination with rituximab in participants with 1 l follicular lymphomaMK-1045 / RituximabMerck & Co. (MSD)Ongoing
Apr 10, 2026A phase 3, randomized, open-label, multicenter study evaluating the efficacy of KITE-753 versus axicabtagene ciloleucel in participants with relapsed and/or…KITE-753Kitepharma IncOngoing
Apr 9, 2026A global stufy of novel agents in paediatric and adolescent replapsed and refractory B-cell Non-Hodgkin lymphomaREGN1979 / ADCT-402 / EtopophosC17 CouncilPending
Mar 11, 2026A phase 1/2 open-label, multicenter study evaluating the safety and efficacy of KITE-363 or KITE-753, autologous ANTI-CD19/CD20 car T-cell therapies, in…KITE-753Kitepharma IncOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 299
Oct 2, 2026JaypircaTreatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known…Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and CompanyApproved
May 13, 2026BeqalziTreatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including…BeOne Medicines USA, Inc.Approved
Mar 20, 2026OpdivoIn combination with doxorubicin, vinblastine, and dacarbazine (AVD), for the treatment of adult and pediatric patients 12 years and older…Bristol-Myers Squibb CompanyApproved
Feb 5, 2026YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12…Kite Pharma, Inc.Approved
Dec 19, 2025Lunsumio VeloTreatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapyGenentech, Inc.Approved
Dec 4, 2025BreyanziTreatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least 2 prior lines of systemic…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Dec 4, 2025BreyanziTreatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least 2 prior lines of systemic…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Dec 4, 2025BreyanziTreatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least 2 prior lines of systemic…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Dec 3, 2025JaypircaTreatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have…Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and CompanyApproved
Nov 18, 2025EpkinlyIn combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL)Genmab US, Inc.Approved
Jun 18, 2025MonjuviIn combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL)Incyte CorporationApproved
Jan 16, 2025CalquenceIn combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who…Acerta Pharma, LLC (a member of the AstraZeneca Group)Approved
Aug 7, 2024LymphirTreatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic…Citius Oncology, Inc.Approved
Jun 26, 2024EpkinlyTreatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapyGenmab US, Inc.Approved
May 30, 2024BreyanziTreatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic…Juno Therapeutics, Inc.Approved

Medicines authorised in the EU

Newest first; 15 of 43
Jul 17, 2025AucatzylObecabtagene autoleucelAutolus GmbHEMA ↗
Sep 19, 2024ItuxrediRituximab · biosimilarReddy Holding GmbHEMA ↗
Aug 22, 2024OrdsponoOdronextamab · orphanRegeneron Ireland Designated Activity Company (DAC)EMA ↗
Jul 26, 2024Dasatinib Accord HealthcareDasatinib · genericAccord Healthcare S.L.U.EMA ↗
Oct 30, 2023JaypircaPirtobrutinibEli Lilly Nederland B.V.EMA ↗
Sep 22, 2023TepkinlyEpcoritamabAbbVie Deutschland GmbH & Co. KGEMA ↗
Sep 15, 2023EnrylazeCrisantaspaseJazz Pharmaceuticals Ireland LimitedEMA ↗
Jul 7, 2023ColumviGlofitamabRoche Registration GmbHEMA ↗
Dec 20, 2022ZynlontaLoncastuximab tesirineSwedish Orphan Biovitrum ABEMA ↗
Jun 3, 2022LunsumioMosunetuzumab · orphanRoche Registration GmbHEMA ↗
Apr 4, 2022BreyanziLisocabtagene maraleucelBristol-Myers Squibb Pharma EEIGEMA ↗
Aug 26, 2021MinjuviTafasitamab · orphanIncyte Biosciences Distribution B.V.EMA ↗
Jan 7, 2021ElzonrisTagraxofusp · orphanStemline Therapeutics B.V.EMA ↗
Dec 14, 2020TecartusBrexucabtagene autoleucel · orphanKite Pharma EU B.V.EMA ↗
Nov 16, 2020PhelinunMelphalanEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.